NT5E and neoplasm: For example, Mittalet al. reported that combination immunotherapy involving an A2A receptor antagonist (SCH58261) and immune checkpoint blockade(anti-CTLA-4, anti-PD-1, or anti-Tim-3 monoclonal antibody) exhibitedgreater potency in inhibiting high expression of CD73 on tumor cellscompared to any monotherapy.64 A comprehensivecompilation of clinical CD73 inhibitors and combination therapiescan be found in Table 1.